Labcorp Holdings Inc Stock Price, News & Analysis

Labcorp (NYSE:LH), a leading provider of innovative laboratory services, has scheduled its Q2 2025 financial results announcement for July 24, 2025, before market opening. The company will host a conference call and webcast at 9:00 AM ET to discuss the results.

Investors can access the earnings release and financial information on Labcorp's Investor Relations website. A webcast replay will be available approximately two hours after the event until July 11, 2026.

Labcorp (NYSE: LH) has launched Labcorp Whole Health Solutions, a comprehensive testing service designed for functional medicine, integrative medicine, and primary care providers. The offering includes specialized test panels and over 1,000 scientifically backed biomarkers focusing on cardiometabolic health, hormones, micronutrients, longevity, and wellness. The service features seven distinct panels including Advanced Cardiometabolic, Comprehensive Nutrient, Longevity and Vitality, and gender-specific hormone and wellness panels. This launch addresses growing market demand, with NIH data showing 37% of U.S. adults (122 million people) used complementary or integrative health approaches in 2022. Patients can access these services through physician offices or Labcorp's network of 2,200+ patient service centers nationwide.

Labcorp (NYSE: LH) has announced a significant expansion of its precision oncology portfolio, introducing new diagnostic solutions and enhanced biopharma services. The company launched new NGS panels for blood cancers, a Rapid AML Panel, and expanded its OmniSeq INSIGHT test to include HRD testing. The expansion includes FDA-approved companion diagnostics for breast and lung cancer patients, and advancements in digital pathology. On the biopharma front, Labcorp is expanding its Plasma Focus liquid biopsy test globally to Geneva and Shanghai, complementing its Tissue Complete assay. The company has also launched an enhanced digital pathology platform using Leica Biosystems scanners and Proscia's Concentriq LS system for improved clinical trials and companion diagnostic development.

SOLVD Health has strengthened its Board of Directors with the appointments of Mike Aicher and Vince Cebula. Aicher, a diagnostics pioneer with over 30 years of executive experience, co-founded National Genetics Institute (acquired by Labcorp) and previously led Labcorp's Esoteric Business Units, generating over $1 billion in annual revenue. Cebula brings extensive financial expertise from roles at Oaktree Capital Management and Jefferies Capital Partners.

These strategic appointments come as SOLVD Health advances its proprietary diagnostics platform, including the FDA-approved AvertD® test for assessing genetic risk of opioid use disorder (OUD). The company aims to expand its personalized health solutions and precision diagnostics platform to deliver better health outcomes through data-driven innovation.

Labcorp (NYSE: LH), a leading global laboratory services provider, has announced that its Annual Meeting of Shareholders will be held virtually on May 15 at 9:00 a.m. ET. Shareholders and interested parties can access the live webcast through the company's Investor Relations website. The recorded session will remain available for replay for one year following the meeting.

Labcorp reported strong Q1 2025 financial results with total revenue reaching $3.35 billion, up 5.3% from $3.18 billion in Q1 2024. The company's adjusted EPS increased to $3.84 from $3.68, while diluted EPS decreased to $2.52 from $2.69.

Key developments include:

• Launch of Labcorp Plasma Complete, a new liquid biopsy test for cancer treatment
• Introduction of pTau-217/Beta Amyloid 42 Ratio test for Alzheimer's diagnosis
• Strategic collaboration with Inspira Health for hospital laboratory management
• Acquisition of BioReference Health's oncology testing assets

The company updated its 2025 guidance, maintaining revenue growth projections of 6.7% to 8.0% and raising the midpoint of adjusted EPS to $15.70-$16.40. Free cash flow is expected between $1.10-$1.25 billion. Labcorp also announced a quarterly dividend of $0.72 per share, payable June 11, 2025.

Labcorp (NYSE: LH) has expanded its precision oncology portfolio with two groundbreaking solutions. The first is Labcorp Plasma Detect, a blood-based test using whole-genome sequencing to assess recurrence risk in stage III colon cancer patients, which has a nearly 30% recurrence rate within five years. The test can detect circulating tumor DNA (ctDNA) with a detection limit of 0.005% and delivers results in approximately 14 days.

The second solution is the PGDx elio plasma focus Dx, the first FDA-authorized kitted pan-solid tumor liquid biopsy test. This innovative test supports treatment selection through a simple blood draw, with results available in 4-5 days. The test allows clinical laboratories to maintain control over patient specimens and requires only on-site verification for implementation.

Both solutions will be featured at the AACR 2025 Annual Meeting in Chicago, demonstrating Labcorp's commitment to advancing cancer diagnostics and improving patient outcomes.

Labcorp (NYSE: LH) has announced a quarterly cash dividend declaration of $0.72 per share of common stock. The dividend will be paid on June 11, 2025, to stockholders of record at the close of business on May 29, 2025. The announcement comes from the company's Board of Directors, reinforcing their commitment to returning value to shareholders.

Labcorp (NYSE: LH) has launched a groundbreaking blood-based biomarker test nationwide to aid in Alzheimer's disease diagnosis. The pTau-217/Beta Amyloid 42 Ratio test offers results comparable to PET imaging and CSF testing, with 95% sensitivity and specificity.

This innovative immunoassay measures two distinct biomarkers: pTau-217 and Beta Amyloid 42 in ratio, meeting performance criteria to confirm amyloid pathology consistent with Alzheimer's. The test is available at physician offices and Labcorp's 2,000+ Patient Service Centers nationwide, offering a less invasive alternative to current diagnostic methods.

With 6.9 million Americans living with Alzheimer's and diagnosis typically taking 2.8 years from symptom onset, this breakthrough aims to accelerate the diagnostic process. The test is available for both clinical trials and patient care, with data presentation scheduled at the American Association of Neurology's 2025 Annual Meeting in San Diego.